JPRN-UMIN000001798已完成未知
Prevention of cartilage destruction in rheumatoid arthritis by etanercept (PRECEPT study) - PRECEPT study
Team RA, Rheumatosurgery, Osaka City University Medical School0 个研究点目标入组 100 人开始时间: 2009年3月25日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Cases who have Joint destruction on hand and foot, in whom we can't measure modified Sharp score. Except Eetanercept dose, there is no restriction for other medicine use.
研究者
相似试验
进行中（未招募）
不适用
Prevention of clinically manifest rheumatoid arthritis by B cell directed therapy in the earliest phase of the disease.EUCTR2009-010955-29-NLDivision of Clinically Immunology and Rheumatology, AMC
尚未招募
不适用
Prevention of RA by B cell directed therapy.pre-clinical RANL-OMON28176Academic Medical Center/University of Amsterdam, Amsterdam90
未知
不适用
Strategic reduction of joint destruction in rheumatoid arthritisRheumatoid arthritisJPRN-UMIN000001281School of Medicine, University of Occupational and Environmental Health, Japan120
进行中（未招募）
1 期
Treatment tapering in oligoarticular or rheumatoid factor negative polyarticular Juvenile Idiopathic Arthritis with inactive disease on biologic therapy - AJIBIOREMPatients with oligoarticular onset or rheumatoid factor negative polyarticular JIA followed in tertiary care center for paediatric rheumatology.MedDRA version: 19.0Level: PTClassification code 10059176Term: Juvenile idiopathic arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2016-000312-15-FRASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)230
已完成
不适用
Osteogenesis and osteoclast inhibition in rheumatoid arthritis patients after more than 4 years of treatment with bisphosphonates or bisphosphonates with pitavastatiMusculoskeletal DiseasesOther rheumatoid arthritisRheumatoid arthritisISRCTN45993953Tokyo Metropolitan Bokutoh Hospital (Japan)77